A splicing variant of Merlin promotes metastasis in hepatocellular carcinoma

Nature Communications

Volumn 6, Issue , 2015, Pages

  Luo, Zai Li ^a,b   Cheng, Shu Qun ^a   Shi, Jie ^a   Zhang, Hui Lu ^a   Zhang, Cun Zhen ^a   Chen, Hai Yang ^a   Qiu, Bi Jun ^d   Tang, Liang ^a   Hu, Cong Li ^a   Wang, Hong Yang ^a,d   Li, Zhong ^c,e  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e Shanghai Institute of Cell Therapy Research   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; EZRIN; MERLIN; MOESIN; PROTEIN VARIANT; RADIXIN; ACTIN BINDING PROTEIN; CTNNB1 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; MEMBRANE PROTEIN;

CANCER; CELLS AND CELL COMPONENTS; CYTOPLASM; GENE EXPRESSION; PHENOTYPE; PROTEIN; TUMOR;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; CYTOPLASM; EPITHELIAL MESENCHYMAL TRANSITION; EXON; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHENOTYPE; PORTAL VEIN THROMBOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA SPLICING; TUMOR THROMBUS; WILD TYPE; ALTERNATIVE RNA SPLICING; GENETICS; LIVER TUMOR; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PORTAL VEIN; SECONDARY; THROMBOSIS; TUMOR CELL LINE;

ALTERNATIVE SPLICING; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOPLASM; CYTOSKELETAL PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; NEUROFIBROMIN 2; PORTAL VEIN; THROMBOSIS;

EID: 84943606376     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9457     Document Type: Article

References (43)

1. Ishikawa, T. et al. Percutaneous transhepatic portal vein stent placement can improve prognosis for hepatocellular carcinoma patients with portal vein tumor thrombosis. Hepatogastroenterology 61, 413-416 (2014).
2. Bosch, F. X., Ribes, J., Diaz, M. & Cleries, R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127, S5-S16 (2004).
3. Zhang, J. et al. RMP promotes venous metastases of hepatocellular carcinoma through promoting IL-6 transcription. Oncogene 34, 1575-1583 (2015).
4. Pecina-Slaus, N. Merlin, the NF2 gene product. Pathol. Oncol. Res. 19, 365-373 (2013).
5. Merel, P. et al. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer 13, 211-216 (1995).
6. Arakawa, H., Hayashi, N., Nagase, H., Ogawa, M. & Nakamura, Y. Alternative splicing of the NF2 gene and its mutation analysis of breast and colorectal cancers. Hum. Mol. Genet. 3, 565-568 (1994).
7. Kanai, Y., Tsuda, H., Oda, T., Sakamoto, M. & Hirohashi, S. Analysis of the neurofibromatosis 2 gene in human breast and hepatocellular carcinomas. Jpn J. Clin. Oncol. 25, 1-4 (1995).
8. Lallemand, D. et al. Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene 28, 854-865 (2009).
9. McClatchey, A. I. et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 12, 1121-1133 (1998).
10. Lallemand, D., Curto, M., Saotome, I., Giovannini, M. & McClatchey, A. I. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev. 17, 1090-1100 (2003).
11. Savio, M. et al. Degradation of p21CDKN1A after DNA damage is independent of type of lesion, and is not required for DNA repair. DNA Repair (Amst) 8, 778-785 (2009).
12. Liu, Y., El-Naggar, S., Darling, D. S., Higashi, Y. & Dean, D. C. Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development 135, 579-588 (2008).
13. Benhamouche, S. et al. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev. 24, 1718-1730 (2010).
14. Zhang, N. et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev. Cell 19, 27-38 (2010).
15. Camargo, F. D. et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr. Biol. 17, 2054-2060 (2007).
16. Manchanda, P. K. et al. Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors. Oncogene 32, 3491-3499 (2013).
17. Sherman, L. et al. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 15, 2505-2509 (1997).
18. Gutmann, D. H., Geist, R. T., Xu, H., Kim, J. S. & Saporito-Irwin, S. Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum. Mol. Genet. 7, 335-345 (1998).
19. Zhou, L. et al. Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/beta-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways. Neoplasia 13, 1101-1112 (2011).
20. Lau, Y. K. et al. Merlin is a potent inhibitor of glioma growth. Cancer Res. 68, 5733-5742 (2008).
21. Kressel, M. & Schmucker, B. Nucleocytoplasmic transfer of the NF2 tumor suppressor protein merlin is regulated by exon 2 and a CRM1-dependent nuclear export signal in exon 15. Hum. Mol. Genet. 11, 2269-2278 (2002).
22. Laulajainen, M., Melikova, M., Muranen, T., Carpen, O. & Gronholm, M. Distinct overlapping sequences at the carboxy-terminus of merlin regulate its tumour suppressor and morphogenic activity. J. Cell Mol. Med. 16, 2161-2175 (2012).
23. Pykett, M. J., Murphy, M., Harnish, P. R. & George, D. L. The neurofibromatosis 2 (NF2) tumor suppressor gene encodes multiple alternatively spliced transcripts. Hum. Mol. Genet. 3, 559-564 (1994).
24. Bianchi, A. B. et al. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat. Genet. 6, 185-192 (1994).
25. Thurneysen, C. et al. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 64, 140-147 (2009).
26. Giovannini, M. et al. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev. 13, 978-986 (1999).
27. Deguen, B. et al. Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene. Int. J. Cancer 77, 554-560 (1998).
28. Hanemann, C. O. Magic but treatable? Tumours due to loss of merlin. Brain 131, 606-615 (2008).
29. Bianchi, A. B. et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl Acad. Sci. USA 92, 10854-10858 (1995).
30. Rustgi, A. K. et al. Neurofibromatosis 2 gene in human colorectal cancer. Cancer Genet. Cytogenet. 84, 24-26 (1995).
31. Jacoby, L. B., MacCollin, M., Barone, R., Ramesh, V. & Gusella, J. F. Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosomes Cancer 17, 45-55 (1996).
32. He, C., Zhou, F., Zuo, Z., Cheng, H. & Zhou, R. A global view of cancer-specific transcript variants by subtractive transcriptome-wide analysis. PLoS ONE 4, e4732 (2009).
33. Fackenthal, J. D. & Godley, L. A. Aberrant RNA splicing and its functional consequences in cancer cells. Dis. Model Mech. 1, 37-42 (2008).
34. Yi, C., Wilker, E. W., Yaffe, M. B., Stemmer-Rachamimov, A. & Kissil, J. L. Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2. Cancer Res. 68, 7932-7937 (2008).
35. Shaw, R. J. et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev. Cell 1, 63-72 (2001).
36. Zhan, Y. & Chadee, D. N. Inhibition of Cdc42-mediated activation of mixed lineage kinase 3 by the tumor suppressor protein merlin. Small GTPases 1, 183-186 (2010).
37. Zhan, Y. et al. Regulation of mixed lineage kinase 3 is required for Neurofibromatosis-2-mediated growth suppression in human cancer. Oncogene 30, 781-789 (2011).
38. Bosco, E. E., Nakai, Y., Hennigan, R. F., Ratner, N. & Zheng, Y. NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation. Oncogene 29, 2540-2549 (2010).
39. Wang, T. et al. Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma. Br. J. Cancer. 102, 1618-1626 (2010).
40. Dong, L. W. et al. Prognostic significance of Beclin 1 in intrahepatic cholangiocellular carcinoma. Autophagy 7, 1222-1229 (2011).
41. Chen, H. et al. Low glucose promotes CD133mAb-elicited cell death via inhibition of autophagy in hepatocarcinoma cells. Cancer Lett. 336, 204-212 (2013).
42. Chiba, T. et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44, 240-251 (2006).
43. Shi, G. M. et al. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J. Cancer Res. Clin. Oncol. 134, 1155-1163 (2008).